PeerView Family Medicine & General Practice CME/CNE/CPE Video Podcast

Go online to PeerView.com/JWM860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, experts in the management of patients with hormone receptor–positive breast cancer discuss the latest advances with TROP2-targeting antibody–drug conjugates (ADCs). Produced in collaboration with Living Beyond Breast Cancer and METAvivor, this program features a patient explaining her journey from diagnosis to participation in an important clinical trial, and faculty providing practical guidance for using TROP2-targeting ADCs in the individualized care of patients with breast cancer. Upon completion of this activity, participants should be better able to: Summarize the rationale, mechanism of action, and expanding clinical role of TROP2-targeting therapies in breast cancer; Integrate the latest safety and efficacy evidence on TROP2-targeting agents in the treatment of different subtypes of breast cancer, including TNBC and HR+ breast cancer; Develop individualized management plans for patients with breast cancer that incorporate TROP2-targeting therapies using the latest clinical evidence and current practice guidelines to inform daily practice; and Apply a team-based approach to care that incorporates shared decision-making and patient counseling/education and leverages effective interprofessional collaboration and care coordination.

Go online to PeerView.com/WKU860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Hypertrophic cardiomyopathy (HCM) is estimated to affect as many as 15 to 20 million people worldwide. However, it remains frequently undetected, because its symptoms are often nonspecific or mistaken for more common conditions. In this discussion-based activity, leading experts on HCM get to the heart of the matter, diagnosis and treatment, as they review guideline recommendations on imaging for diagnosis and examine current and novel treatment options, including small-molecule myosin inhibitors, as a means to improve patient outcomes and quality of life. Upon completion of this activity, participants should be better able to: Differentially diagnose patients suspected of having HCM consistent with current guidance using appropriate cardiac imaging techniques; Apply the latest recommendations and current guidance for diagnosing, evaluating, and managing patients with HCM in a collaborative care model; and Incorporate emerging therapies for managing patients with HCM based on their efficacy, safety, and ability to address the unmet needs of patients and the pathophysiology of HCM.

Go online to PeerView.com/DBP860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert on obesity management discusses current evidence for anti-obesity medications and shares evidence-based strategies to individualize weight-loss regimens and improve health outcomes. Upon completion of this activity, participants should be better able to: Recognize the role of weight-loss pharmacotherapy for reducing risks and addressing obesity as a chronic disease, including effects on appetite regulation, metabolic adaptation, and preventing/managing obesity-related complications, adjunct to lifestyle modification; Assess current guidance and available long-term efficacy and safety data for current and emerging weight-loss pharmacotherapies in people with or at risk for obesity; and Incorporate weight-loss pharmacotherapy, as appropriate, into individualized, evidence-based treatment plans for long-term obesity management.

Go online to PeerView.com/TFR860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Who holds the key that can unlock the door to vision-saving treatments for patients with diabetic retinopathy (DR) and diabetic macular edema (DME)? The answer is primary diabetes care professionals: Timely screening and referral to eye care professionals can make a real difference between good vision and blindness for patients with DR/DME. The diagnosis and treatment of DR/DME has advanced greatly in the last decade. What can endocrinologists, diabetologists, and primary diabetes care professionals tell their patients to expect when they meet with a retina specialist? In this activity, based on a recent PeerView Live event, leading experts take a well-rounded look at the screening, diagnosis, and referral for treatment of individuals with DR/DME, including a practical review of the evidence for current and emerging treatment options. The experts discuss patient cases with varying degrees of urgency for referral, offering a glimpse into how decisions made by primary diabetes care professionals can speed access to the appropriate eye care professional to directly benefit and improve outcomes for patients with, or at risk for, DR/DME. Upon completion of this activity, participants should be better able to: Describe the roles of diabetes specialists in the screening and referral process for DR/DME and other diabetic eye diseases; Coordinate timely and appropriate referrals to eye care specialists who can utilize effective treatment regimens for DR/DME and other diabetic eye diseases; and Incorporate interprofessional and multidisciplinary strategies to overcome barriers to referral using an integrated system of care approach for screening, diagnosis, and treatment of vision-threatening diabetic eye complications such as DR/DME.

Go online to PeerView.com/REK860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. For individuals with multiple sclerosis (MS), “invisible symptoms” that include cognitive changes and fatigue exacerbate the burden of disease. Emerging evidence indicates that in addition to providing high efficacy, safety, tolerability, and patient convenience, sphingosine 1-phosphate receptor (S1PR) modulators may yield important benefits related to loss of cortical gray matter and whole brain volume, addressing cognition as well as multiple other aspects of MS. At a recent live event, our expert faculty reviewed the mechanism of action of S1PR modulators and their important role in MS care, with a focus on the clinically relevant distinctions among members of this class—from first-generation fingolimod to the more recently introduced siponimod, ozanimod, and ponesimod. The faculty discussed the role of agent-specific characteristics such as relative selectivity and off-target effects in individualized treatment planning—reviewing key trial data on patient outcomes and concluding with a case-based workshop addressing treatment selection, shared decision-making, and COVID-19 vaccination. Upon completion of this activity, participants should be better able to: Discuss the rationale for the modulation of S1P function as a therapeutic approach in multiple sclerosis (MS) in the context of disease pathophysiology; Individualize S1PR modulator therapy for patients with MS based on the latest evidence on safety, efficacy, and the potential impact on physical and cognitive outcomes; and Apply a patient-centered, team-based approach to treatment selection and sequencing in MS based on the patient’s disease activity, treatment preferences and goals, and therapeutic options.

Go online to PeerView.com/RBU860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert discusses the recognition of axial spondyloarthritis (axSpA) and integrating the latest evidence into the management of patients with axSpA. Upon completion of this activity, participants should be better able to: Identify the specific domains of axial spondyloarthritis (axSpA) and their relationship to quality of life; Apply classification criteria and diagnostic tests into clinical practice to identify axSpA in patients with inflammatory back pain; Assess efficacy and safety data related to novel biologic options for axSpA, recognizing the potential clinical impact on the management of patients who do not respond well to traditional pharmacologic therapies; Employ treatment plans for individual patients with axSpA in accordance with current evidence, expert recommendations, and patient needs and preferences; and Collaborate with rheumatologists to provide optimal treatment and longitudinal support for patients with axSpA.

Go online to PeerView.com/XJG860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Systemic lupus erythematosus (SLE) is an autoimmune disease associated with substantial morbidity and mortality, especially in women. The disease causes progressive damage to multiple organ systems and reduces quality of life. Improving your understanding of SLE heterogeneity at the clinical and mechanistic level can drive significant improvements across the care spectrum. In this expert-driven activity, you will hear the latest clinical evidence presented during the European Alliance of Associations for Rheumatology (EULAR) 2022 Congress in Copenhagen, Denmark, with regard to the current treatment options for SLE and the potential for TYK2 inhibitors to change SLE management. Upon completion of this activity, participants should be better able to: Recognize the burden of SLE and the impact of delayed or suboptimal treatment on patient outcomes; Describe the mechanistic rationale and recent safety and efficacy data supporting a role for targeting TYK2 and BTK as potential therapeutic approaches in SLE; and Identify SLE patients who might benefit from emerging TYK2 and BTK inhibition strategies through clinical trial enrollment and recognizing potential implications for a future treatment paradigm.

Go online to PeerView.com/REA860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Listen to our expert faculty as they discuss new and emerging therapies for AA and AD, with a focus on mechanisms of action, efficacy and safety profiles, nuances of administration and use, and risk:benefit profile. You will also hear about novel therapies in late-stage development for the treatment of moderate to severe AD and AA. The Late Night inExchange format is designed to meet the educational needs of clinicians with practice-relevant education presented in an engaging multi-faculty discussion format that brings knowledge to life. Through this format, learners will be better able to see how conceptual knowledge of AA and AD translates to actual practice. Upon completion of this activity, participants should be better able to: Appropriately assess the severity of atopic dermatitis (AD) and alopecia areata (AA) to determine the best treatment strategy in individual patients, recognizing wide variation in clinical presentation among different ethnicities; Describe advances in understanding of AD and AA pathophysiology that have led to the development of therapies with specific molecular targets; Assess new and emerging treatments for AD and AA in terms of their mechanisms of action, efficacy and safety profiles, nuances of administration and use, and other factors relevant to the benefit:risk profile; and Employ a holistic and team-based healthcare approach to the management of AD and AA that addresses both the physical and psychological comorbidities of disease.

Go online to PeerView.com/DGJ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Are you up to date on recent evidence on acute lymphoblastic leukemia (ALL) emerging from major scientific congresses? In this activity, an ALL specialist explores recent evidence presented at the 2022 American Society of Clinical Oncology (ASCO) and European Hematology Association (EHA) annual meetings on developments in various treatment modalities for ALL. Watch this video to hear about the latest evidence and practical applications in asparaginase use in chemotherapy protocols, including important dosing and safety data on recombinant Erwinia; get updated on longer-term outcomes with CAR-T therapy in adult and pediatric patients and hear practical considerations when using CAR-T options; and learn about emerging chemo-sparing TKI plus bispecific combinations in Ph-positive ALL. Upon completion of this activity, participants should be better able to: Summarize new evidence on multi-faceted strategies for ALL management based on modern chemotherapy protocols, antibody-based approaches, cellular therapy, and TKIs; Cite evidence supporting the use of novel asparaginase compounds for ALL in the context of asparaginase toxicity/hypersensitivity, including in pediatric, AYA, and adult populations; and Apply new science to the team-based management of ALL, including when managing asparaginase hypersensitivity or toxicity, developing TKI-based protocols in Ph-positive disease, or when utilizing novel immunotherapy-based approaches in patient care.

Go online to PeerView.com/EWZ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Solid organ transplant recipients may be at increased risk for COVID-19 because they are immunosuppressed and less likely to mount effective immune responses to vaccination. In this educational symposium based on a live event, a panel of expert faculty address the identification of transplant patients who would likely derive benefit from anti-SARS-CoV-2 monoclonal antibodies (mAbs) and strategies that can be used to overcome barriers to COVID-19 pre-exposure prophylaxis access. In addition, they provide guidance on mAb qualities and clinical profiles and shared decision-making strategies to customize mAb pre-exposure prophylaxis at the point of care for transplant recipients needing protection against COVID-19. After participating in this activity, the learner will demonstrate the ability to: Identify post-transplant patients who would likely derive benefit from pre-exposure prophylaxis with anti-SARS-CoV-2 monoclonal antibodies (mAbs); Use strategies to overcome barriers to COVID-19 pre-exposure prophylaxis access for post-transplant patients; and Incorporate evidence-based recommendations and guidelines, mAb qualities and clinical profiles, and shared decision-making into strategies to customize mAb pre-exposure prophylaxis at point of care for post-transplant patients needing protection against COVID-19.